Genocea Biosciences Inc. buy Quitte
Summary
This prediction ended on 22.05.19 with a price of €4.12. The price of Genocea Biosciences Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -22.84%. Quitte has 50% into this predictionGenocea Biosciences (Symbol GNCA) (WKN A2PK76) is a publicly traded, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel vaccines and immunotherapies for various infectious diseases and cancer. With a unique approach to unlocking the power of T-cells in rapid vaccine and immunotherapy discovery, the company has established a robust pipeline targeting a wide spectrum of viral, bacterial, and parasitic diseases as well as oncology indications. Notable programs include GEN-003 for genital herpes and GEN-009, an innovative and personalized neoantigen cancer vaccine. Listed on the Nasdaq stock exchange, Genocea is dedicated to improving patient outcomes through cutting-edge research, expertise in immune targeting, and a strong commitment to scientific innovation.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Genocea Biosciences Inc. | - | - | - | - |
| iShares Core DAX® | -1.020% | 0.271% | 13.941% | 56.827% |
| iShares Nasdaq 100 | -3.122% | -1.929% | 1.920% | 83.028% |
| iShares Nikkei 225® | 0.649% | 6.582% | 21.176% | 50.695% |
| iShares S&P 500 | -0.142% | -0.295% | 1.363% | 57.560% |
Comments by Quitte for this prediction
In the thread Genocea Biosciences Inc. diskutieren
geh wieder rein
Quitte stimmt am 08.04.2019 dem Buy-Gesamtsentiment mit dem Kursziel 1.0$ zu.
Stopped prediction by Quitte for Genocea Biosciences Inc.
Genocea Biosciences Inc.
05.01.21
05.01.22
06.01.22
Genocea Biosciences Inc.
05.06.18
05.12.18
05.12.18